Short answer
Henry Schein (HSIC) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 27, 2026. Quarterly revenue was $3.5B (up 6.7% year over year) with net income of $94M.
Q2 2026 key financials · XBRL
- Revenue
- $3.5B
- +6.7% YoY · +2.7% QoQ
- Net income
- $94M
- +9.3% YoY · −12.1% QoQ
- Operating margin
- 4.9%
- Gross margin
- 31.8%
- EPS (diluted)
- $0.82
- +17.1% YoY · −10.9% QoQ
Source: XBRL data from the Henry Schein (HSIC) Q2 2026 10-Q on SEC EDGAR. USD.
Henry Schein Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3,458M, up $218M or 6.7% YoY from $3,240M
- Global Specialty Products best-performing segment, sales $419M, up 8.7% YoY
- Global Medical weakest major product line, sales $1,057M, up 4.0% YoY
- Operating income $171M vs $151M YoY; restructuring charges $29M vs $23M
- Operating cash flow $145M vs $157M; investing outflow $128M vs $197M
Risk Factors
- No material changes to 10-K risk factors for year ended December 27, 2025
- Carried-forward risks remain the most significant disclosed exposures
- Share repurchases reduced available authorization to $455 million as of June 27, 2026
- 10-Q provides no newly triggered regulatory, legal, operational, competitive, or financial risk factors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Henry Schein quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.